PDLI-
There were allegations and concerns regarding the willful mismanagement of PDL by McDade. The hiring of a new CEO and PDL's ongoing strategic review could result in the sale of the company.
Royalty revs were solid at $80M for 2Q, Cardene sales, which were $40.5M, appear to have gained momentum, PDL could achieve '07 product sales guidance of $200M.
DNA product sales of Actemra and Cimzia could add growth in royalty revs. They have initiated the 2nd ph.III study Nuvion in UC, and looks like it has long-term safety and durability. Also the presentation of full ph.II results for Daclizumab in MS
at ECTRIMS in 4Q07 should be positive for them.
I bought a year ago @ $16.8 and holding, I think there is still upside for the stock.
Idit
